Practical therapy for primary autoimmune hemolytic anemia in adults
- 18 August 2022
- journal article
- review article
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 23 (3) , 727-736
Abstract
Background and aim Autoimmune hemolytic anemias (AIHA) constitute a rare and heterogeneous group of diseases whose therapy differs according to the type of antibody involved in the genesis of the disease and the existence or not of an identified cause. With the aim of providing a practical guide for the therapy of AIHA, we summarize the emergency therapy and general measures habitually used in all forms of AIHA, as well as the specific treatment of the most frequent primary forms of AIHA: primary warm AIHA and AIHA from cold agglutinin disease (AIHA from CAD). We discuss the dependence of the treatment of the secondary forms on their underlying causes and the changes in the treatment of the primary forms in recent years. Methods We examined the options available for the treatment of primary warm AIHA and AIHA from CAD. Results We found many differences and only one similarity in their treatment. Discussion The differences, particularly due to the non-responsiveness of AIHA from CAD to many treatments useful for primary warm AIHA, such as steroids, splenectomy and immunosuppressive agents, must be considered in the face of each, single case of AIHA. Preliminary identification of the type of antibody involved in the genesis of the disease and careful exclusion of a secondary form are particularly important. Rituximab plays a central role in the treatment of primary warm AIHA and AIHA from CAD.Keywords
This publication has 25 references indexed in Scilit:
- Bortezomib-based antibody depletion for refractory autoimmune hematological diseasesBlood Advances, 2016
- A randomized and double‐blind controlled trial evaluating the safety and efficacy of rituximab for warm auto‐immune hemolytic anemia in adults (the RAIHA study)American Journal of Hematology, 2016
- Current treatment strategies in autoimmune hemolytic disordersExpert Review of Hematology, 2015
- The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2015
- A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemiaBritish Journal of Haematology, 2013
- The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopeniaBlood, 2011
- High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin diseaseBlood, 2010
- Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin diseaseBlood, 2009
- Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patientsBlood, 2004
- Favourable response to therapy with the anti‐CD20 monoclonal antibody rituximab in primary chronic cold agglutinin diseaseBritish Journal of Haematology, 2001